<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">28836659</PMID>
      <DateCompleted>
        <Year>2017</Year>
        <Month>09</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>06</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1469-493X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>8</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2017</Year>
              <Month>Aug</Month>
              <Day>24</Day>
            </PubDate>
          </JournalIssue>
          <Title>The Cochrane database of systematic reviews</Title>
          <ISOAbbreviation>Cochrane Database Syst Rev</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Zonisamide for essential tremor.</ArticleTitle>
        <Pagination>
          <StartPage>CD009684</StartPage>
          <MedlinePgn>CD009684</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">CD009684</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/14651858.CD009684.pub2</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Essential tremor (ET) is one of the most common movement disorders. The treatment is primarily based on pharmacological agents. Although primidone and propranolol are well established treatments in clinical practice, they can be ineffective in 25% to 55% of patients, and can produce serious adverse events in a large percentage of them. For these reasons, it may be worthwhile evaluating the treatment alternatives for ET. Zonisamide has been suggested as a potentially useful agent for the treatment of ET but there is uncertainty about its efficacy and safety.</AbstractText>
          <AbstractText Label="OBJECTIVES">To assess the effect on functional abilities and the safety profile of zonisamide in adults with essential tremor (ET).</AbstractText>
          <AbstractText Label="SEARCH METHODS">We carried out a systematic search, without language restrictions to identify all relevant trials. We searched CENTRAL, MEDLINE, Embase, NICE, ClinicalTrials.gov, and the WHO International Clinical Trials Registry Platform (ICTRP) to January 2017. We searched BIOSIS Citation Index (2000 to January 2017) for conference proceedings. We handsearched grey literature and examined the reference lists of identified studies and reviews.</AbstractText>
          <AbstractText Label="SELECTION CRITERIA">We included all randomised controlled trials (RCTs) of zonisamide versus placebo or any other treatment. We included studies in which the diagnosis of ET was made according to accepted and validated diagnostic criteria. We excluded studies conducted in patients presenting secondary forms of tremor or reporting only neurophysiological parameters to assess outcomes.</AbstractText>
          <AbstractText Label="DATA COLLECTION AND ANALYSIS">Two review authors independently collected and extracted data using a data collection form. We assessed the risk of bias and the quality of evidence.We used inverse variance methods for continuous outcomes and measurement scales. We compared differences between treatment groups as mean differences. We combined results for dichotomous outcomes using Mantel-Haenszel methods and obtained risk differences to compare treatment groups. We used Review Manager 5 software for data management and analysis.</AbstractText>
          <AbstractText Label="MAIN RESULTS">We only considered one study eligible for this review (20 participants). Assessments of risk of bias for most domains were unclear or low. Adverse events were only reported in participants from the zonisamide group, making it possible that they were aware of treatment group assignment. We are uncertain as to the effects of zonisamide on motor tasks (mean difference (MD) -0.00, 95% confidence interval (CI) -1.51 to 1.51, very low-quality evidence) and functional disabilities (MD -0.30, 95% CI -1.23 to 0.63, very low-quality evidence) when compared with placebo. Three participants in the zonisamide group (30%) and two participants in the placebo group (20%) discontinued the treatment and withdrew from the study for any reason (very low-quality evidence), however the increased risk of withdrawal in the zonisamide group was statistically non-significant (risk difference (RD) 0.1, 95% CI -0.28 to 0.48). Six participants in the zonisamide group (60%) and none of the participants in the placebo group (0%) developed adverse events (AEs), with a RD of 0.60 (95% CI 0.28 to 0.92; very low quality evidence). The most common AEs, experienced with zonisamide treatment, were headache, nausea, fatigue, sleepiness, and diarrhoea. Quality of life was not assessed in the study included.</AbstractText>
          <AbstractText Label="AUTHORS' CONCLUSIONS">Based on currently available data, there is insufficient evidence to assess the efficacy and safety of zonisamide treatment for ET.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bruno</LastName>
            <ForeName>Elisa</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department GF Ingrassia, Section of Neurosciences, University of Catania, Catania, Italy, 95123.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nicoletti</LastName>
            <ForeName>Alessandra</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Filippini</LastName>
            <ForeName>Graziella</ForeName>
            <Initials>G</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Quattrocchi</LastName>
            <ForeName>Graziella</ForeName>
            <Initials>G</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Colosimo</LastName>
            <ForeName>Carlo</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zappia</LastName>
            <ForeName>Mario</ForeName>
            <Initials>M</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
          <PublicationType UI="D000078182">Systematic Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2017</Year>
          <Month>08</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cochrane Database Syst Rev</MedlineTA>
        <NlmUniqueID>100909747</NlmUniqueID>
        <ISSNLinking>1361-6137</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007555">Isoxazoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>459384H98V</RegistryNumber>
          <NameOfSubstance UI="D000078305">Zonisamide</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="UpdateOf">
          <RefSource>doi: 10.1002/14651858.CD009684</RefSource>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020329" MajorTopicYN="N">Essential Tremor</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007555" MajorTopicYN="N">Isoxazoles</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000078305" MajorTopicYN="N">Zonisamide</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>EB: none. 
AN: none. 
GQ: none. 
CC: none. 
GF: none. 
MZ: none.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>8</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2017</Year>
          <Month>9</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>8</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28836659</ArticleId>
        <ArticleId IdType="pmc">PMC6483684</ArticleId>
        <ArticleId IdType="doi">10.1002/14651858.CD009684.pub2</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>References to studies included in this review</Title>
        <ReferenceList>
          <Title>Zesiewicz 2006 {published data only}</Title>
          <Reference>
            <Citation>Zesiewicz TA, 
Ward CL, 
Hauser RA, 
Sanchez‐Ramos J, 
Staffetti JF, 
Sullivan KL. 
A double‐blind placebo‐controlled trial of zonisamide (Zonegran) in the treatment of essential tremor. 
Movement Disorders 2006;22(2):279‐82. 
</Citation>
          </Reference>
        </ReferenceList>
      </ReferenceList>
      <ReferenceList>
        <Title>References to studies excluded from this review</Title>
        <ReferenceList>
          <Title>Bermejo 2007 {published data only}</Title>
          <Reference>
            <Citation>Bermejo PE. 
Zonisamide in patients with essential tremor and Parkinson's disease. 
Movement Disorders 2007;22(14):2137‐8. 
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Bermejo 2008 {published data only}</Title>
          <Reference>
            <Citation>Bermejo PE, 
Ruiz‐Huete C, 
Dorado R, 
Anciones B. 
Zonisamide in refractory essential tremor. 
Revista de Neurologia 2008;46(3):139‐42. 
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Handforth 2009 {published data only}</Title>
          <Reference>
            <Citation>Handforth A, 
Martin FC, 
Kang GA, 
Vanek Z. 
Zonisamide for essential tremor: an evaluator‐blinded study. 
Movement Disorders 2009;24(3):437‐40. 
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Ondo 2007 {published data only}</Title>
          <Reference>
            <Citation>Ondo WG. 
Zonisamide for essential tremor. 
Clinical Neuropharmacology 2007;30(6):345‐9. 
</Citation>
          </Reference>
        </ReferenceList>
      </ReferenceList>
      <ReferenceList>
        <Title>References to studies awaiting assessment</Title>
        <ReferenceList>
          <Title>Morita 2005 {published data only}</Title>
          <Reference>
            <Citation>Morita S, 
Miwa H, 
Kondo T. 
Effect of zonisamide on essential tremor: a pilot crossover study in comparison with arotinolol. 
Parkinsonism and Related Disorders 2005;11(2):101‐3. 
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Song 2008 {published data only}</Title>
          <Reference>
            <Citation>Song IU, 
Kim JS, 
Lee SB, 
Ryu SY, 
An JY, 
Kim HT, 
et al. 
Effects of zonisamide on isolated head tremor. 
European Journal of Neurology 2008;15(11):1212‐5. 
</Citation>
          </Reference>
        </ReferenceList>
      </ReferenceList>
      <ReferenceList>
        <Title>Additional references</Title>
        <ReferenceList>
          <Title>Atkins 2004</Title>
          <Reference>
            <Citation>Atkins D, 
Best D, 
Briss PA, 
Eccles M, 
Falck‐Ytter Y, 
Flottorp S, 
et al. 
GRADE Working Group. 
Grading quality of evidence and strength of recommendations. 
BMJ 2004;328(7454):1490.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Bain 1997</Title>
          <Reference>
            <Citation>Bain PG. 
The effectiveness of treatments for essential tremor. 
Neurology 1997;3:305‐21.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Bain 1998</Title>
          <Reference>
            <Citation>Bain PG. 
Clinical measurement of tremor. 
Movement Disorders 1998;13 Suppl 3:77‐80.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Bain 2000a</Title>
          <Reference>
            <Citation>Bain P, 
Brin M, 
Deuschl G, 
Elble R, 
Jankovic J, 
Findley L, 
et al. 
Criteria for the diagnosis of essential tremor. 
Neurology 2000;54 Suppl 4:7.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Bain 2000b</Title>
          <Reference>
            <Citation>Bain PG. 
Tremor assessment and quality of life measurements. 
Neurology 2000;54 Suppl 4:26‐9.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Busenbark 1991</Title>
          <Reference>
            <Citation>Busenbark KL, 
Nash J, 
Nash S, 
Hubble JP, 
Koller WC. 
Is essential tremor benign?. 
Neurology 1991;41:1982‐3.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Chouinard 1997</Title>
          <Reference>
            <Citation>Chouinard S, 
Luois ED, 
Fahn S. 
Agreement among movement disorder specialists on the clinical diagnosis of essential tremor. 
Movement Disorders 1997;12(6):973‐6.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Deeks 2011</Title>
          <Reference>
            <Citation>Deeks JJ, 
Higgins JP, 
Altman DG, 
editor(s). 
Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. 
Available from handbook.cochrane.org.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Deuschl 1998</Title>
          <Reference>
            <Citation>Deuschl G, 
Bain P, 
Brin M. 
Consensus Statement of the Movement Disorder Society on Tremor. 
Movement Disorders 1998;13 Suppl 3:2‐23.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Deuschl 2000</Title>
          <Reference>
            <Citation>Deuschl G, 
Koller WC. 
Essential tremor. 
Neurology 2000;54 Suppl 4:1.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Egger 1997</Title>
          <Reference>
            <Citation>Egger M. 
Bias in meta‐analysis detected by a simple, graphical test. 
BMJ 1997;315:629.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Elble 2013</Title>
          <Reference>
            <Citation>Elble R, 
Bain P, 
Forjaz MJ, 
Haubenberger D, 
Testa C, 
Goetz CG, 
et al. 
Task Force Report: scales for screening and evaluating tremor. Critique and recommendations. 
Movement Disorders 2013;28(13):1793‐1800.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Fahn 1993</Title>
          <Reference>
            <Citation>Fahn S, 
Tolosa E, 
Marin C. 
Clinical rating scale for tremor. 
In: Jankovic J, 
Tolosa E editor(s). 
Parkinson's Disease and Movement Disorders. Baltimore: Williams &amp; Wilkins, 1993:225‐34.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Findley 1995</Title>
          <Reference>
            <Citation>Findley LJ, 
Koller W. 
Definitions and behavioural classifications. 
In: Findley LG, 
Koller W editor(s). 
Handbook of Tremor Disorders. New York: Dekker, 1995:1‐5.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>GRADEpro GDT 2015 [Computer program]</Title>
          <Reference>
            <Citation>McMaster University (developed by Evidence Prime). 
GRADEpro GDT. 
Version January 2017. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Haerer 1992</Title>
          <Reference>
            <Citation>Haerer AF, 
Anderson DW, 
Schoenberg BS. 
Prevalence of essential tremor: results from the Copiah county study. 
Archives of Neurology 1992;39:750‐1.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Hansten 2004</Title>
          <Reference>
            <Citation>Hansten PD, 
Horn JR. 
In: Wickersham RM, 
O’Dell, 
JA editor(s). 
Managing clinically important drug interactions. St Louis: Facts &amp; Comparisons, 2004.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Higgins 2003</Title>
          <Reference>
            <Citation>Higgins JPT, 
Thompson SG, 
Deeks JJ, 
Altman DG. 
Measuring inconsistency in meta‐analyses. 
BMJ 2003;327:557‐60.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Higgins 2011</Title>
          <Reference>
            <Citation>Higgins JP, 
Altman DG, 
Sterne JAC, 
editor(s). 
Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. 
Available from handbook.cochrane.org.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Jankovic 1996</Title>
          <Reference>
            <Citation>Jankovic J, 
Schwartz K, 
Clemence J. 
A randomized, double‐blind, placebo controlled study to evaluate botulinum toxin type A in essential tremor. 
Movement Disorders 1996;11:250‐6.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Jankovic 2002</Title>
          <Reference>
            <Citation>Jankovic J. 
Essential tremor: a heterogeneous disorder. 
Movement Disorders 2002;17:638‐44.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Koller 1986</Title>
          <Reference>
            <Citation>Koller W, 
Biary N, 
Cone S. 
Disability in essential tremor: effect of treatment. 
Neurology 1986;36:1001‐4.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Koller 1989</Title>
          <Reference>
            <Citation>Koller WC, 
Vetere‐Overfield B. 
Acute and chronic effects of propranolol and primidone in essential tremor. 
Neurology 1989;39:1587‐8.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Leppik 2004</Title>
          <Reference>
            <Citation>Leppik IE. 
Zonisamide: chemistry, mechanism of action, and pharmacokinetics. 
Seizure 2004;13 Suppl 1:5‐S9; discussion 10.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Liberati 2009</Title>
          <Reference>
            <Citation>Liberati A, 
Altman DG, 
Tetzlaff J, 
Mulrow C, 
Gøtzsche PC, 
Ioannidis JPA, 
et al. 
for the PRISMA Group. 
The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate healthcare interventions: explanation and elaboration. 
BMJ 2009;21:339:b2700.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Louis 1998</Title>
          <Reference>
            <Citation>Louis ED, 
Ford B, 
Lee H. 
Diagnostic criteria for essential tremor. 
Archives of Neurology 1998;55:823‐8.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Louis 2001a</Title>
          <Reference>
            <Citation>Louis ED. 
Clinical practice, essential tremor. 
New England Medical Journal 2001;342(12):887‐91.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Louis 2001b</Title>
          <Reference>
            <Citation>Louis ED, 
Barnes L, 
Wendt KJ, 
Ford B, 
Sangiorgio M, 
Tabbal S, 
et al. 
A teaching videotape for the assessment of essential tremor. 
Movement Disorders 2001;16:89‐93.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Louis 2005</Title>
          <Reference>
            <Citation>Louis ED. 
Essential tremor. 
Lancet Neurology 2005;4:100‐10.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Louis 2010</Title>
          <Reference>
            <Citation>Louis ED, 
Ferreira JJ. 
How common is the most common movement disorder? Update on the worldwide prevalence of essential tremor. 
Movement Disorders 2010;25(5):534‐41.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Murata 2001</Title>
          <Reference>
            <Citation>Murata M, 
Horiuchi E, 
Kanazawa I. 
Zonisamide has beneficial effects on Parkinson's disease patients. 
Neuroscience Research 2001;41:397‐9.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Nakanishi 2003</Title>
          <Reference>
            <Citation>Nakanishi I, 
Kohmoto J, 
Miwa H, 
Kondo T. 
Effect of zonisamide on resting tremor resistant to aniparkinsonian medication. 
No To Shinkei 2003;55:685‐9.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Ondo 2000</Title>
          <Reference>
            <Citation>Ondo W, 
Hunter C, 
Vuong KD, 
Schwartz K, 
Jankovic J. 
Gabapentin for essential tremor: a multiple‐dose, double‐blind, placebo‐controlled trial. 
Movement Disorders 2000;15(4):678‐82.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Ondo 2006</Title>
          <Reference>
            <Citation>Ondo WG, 
Jankovic J, 
Connor JS, 
Pahwa R, 
Elble R, 
Stacy MA, 
et al. 
Topiramate in essential tremor: A double‐blind, placebo‐controlled trial. 
Neurology 2006;66:672‐7.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Pahwa 1998</Title>
          <Reference>
            <Citation>Pahwa R, 
Lyons K, 
Hubble JP, 
Busenbark K, 
Rienerth JD, 
Pahwa A, 
et al. 
Double‐blind placebo‐controlled study of gabapentin in essential tremor. 
Movement Disorders 1998;13:465‐7.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Rajput 1984</Title>
          <Reference>
            <Citation>Rajput AH, 
Offord KP, 
Beard CM, 
Kurland LT. 
Essential tremor in Rochester, Minnesota: a 45‐year study. 
Journal of Neurology, Neurosurgery and Psychiatry 1984;47:466‐70.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Review Manager 2014 [Computer program]</Title>
          <Reference>
            <Citation>Nordic Cochrane Centre, The Cochrane Collaboration. 
Review Manager 5 (RevMan 5). 
Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Salemi 1994</Title>
          <Reference>
            <Citation>Salemi G, 
Savettieri G, 
Rocca WA, 
Meneghini F, 
Saporito V, 
Morgante L, 
et al. 
Prevalence of essential tremor: a door to‐door survey in Terrasini, Sicily. 
Neurology 1994;44:61‐4.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Schnitzler 2009</Title>
          <Reference>
            <Citation>Schnitzler A, 
Munks C, 
Butz M, 
Timmermann L, 
Gross J. 
Synchronized brain network associated with essential tremor as revealed by magnetoencephalography. 
Movement Disorders 2009;24:1629‐35.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Shorvon 2000</Title>
          <Reference>
            <Citation>Shorvon SD. 
Handbook of Epilepsy Treatment. 2nd Edition. Oxford: Blackwell, 2005.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Sibbald 1998</Title>
          <Reference>
            <Citation>Sibbald B, 
Roberts C. 
Understanding controlled trials: Crossover trials. 
BMJ 1998;316(7146):1719–1720.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Snow 1989</Title>
          <Reference>
            <Citation>Snow B, 
Wiens M, 
Hertzman C, 
Calne D. 
A community survey of Parkinson's disease. 
Canadian Medical Association Journal 1989;141:418‐24.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Stacy 2007</Title>
          <Reference>
            <Citation>Stacy MA, 
Elble RJ, 
Ondo WG, 
Wu SC, 
Hulihan J, 
TRS Study Group. 
Assessment of interrater and intrarater reliability of the Fahn–Tolosa–Marin Tremor Rating Scale in essential tremor. 
Movement Disorders 2007;22:833‐8.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Sullivan 2004</Title>
          <Reference>
            <Citation>Sullivan KL, 
Hauser RA, 
Zesiewicz TA. 
Essential Tremor Epidemiology, Diagnosis and Treatment. Lippincott Williams &amp; Wilkins, 2004.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Wasielewski 1998</Title>
          <Reference>
            <Citation>Wasielewski PG, 
Burns JM, 
Koller WC. 
Pharmacologic treatment of tremor. 
Movement Disorders 1998;13 Suppl 3:90‐100.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Zappia 2013</Title>
          <Reference>
            <Citation>Zappia M, 
Albanese A, 
Bruno E, 
Colosimo C, 
Filippini G, 
Martinelli P, 
et al. 
Treatment of essential tremor: a systematic review of evidence and recommendations from the Italian Movement Disorders Association Essential Tremor Committee. 
Journal of Neurology 2013;260(3):714‐40.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Zesiewicz 2002</Title>
          <Reference>
            <Citation>Zesiewicz TA, 
Encarnacion E, 
Hauser RA. 
Management of essential tremor. 
Current Neurology and Neuorscience Reports 2002;2:324‐30.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Zesiewicz 2005</Title>
          <Reference>
            <Citation>Zesiewicz TA, 
Elble R, 
Louis ED, 
Hauser RA, 
Sullivan KL, 
Dewey RB Jr, 
et al. 
Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. 
Neurology 2005;64(12):2008‐20.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Zesiewicz 2007</Title>
          <Reference>
            <Citation>Zesiewicz TA, 
Ward CL, 
Hauser RA, 
Sanchez‐Ramos J, 
Staffetti JF, 
Sullivan KL. 
A double‐blind placebo‐controlled trial of zonisamide (Zonegran) in the treatment of essential tremor. 
Movement Disorders 2007;22:279‐82.
</Citation>
          </Reference>
        </ReferenceList>
        <ReferenceList>
          <Title>Zesiewicz 2011</Title>
          <Reference>
            <Citation>Zesiewicz TA, 
Elble RJ, 
Louis ED, 
Gronseth GS, 
Ondo WG, 
Dewey RB Jr, 
et al. 
Evidence‐based guideline update: treatment of essential tremor: report of the Quality Standards subcommittee of the American Academy of Neurology. 
Neurology 2011;77(19):1752‐5.
</Citation>
          </Reference>
        </ReferenceList>
      </ReferenceList>
      <ReferenceList>
        <Title>References to other published versions of this review</Title>
        <ReferenceList>
          <Title>Bruno 2012</Title>
          <Reference>
            <Citation>Bruno E, 
Nicoletti A, 
Quattrocchi G, 
Colosimo C, 
Filippini G, 
Zappia M. 
Zonisamide for essential tremor. 
Cochrane Database of Systematic Reviews 14 March 2012, Issue 3. 
[DOI: 10.1002/14651858.CD009684]
</Citation>
            <ArticleIdList>
              <ArticleId IdType="doi">10.1002/14651858.CD009684</ArticleId>
            </ArticleIdList>
          </Reference>
        </ReferenceList>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
